Universal Vision Biotechnology Co (3218) Fair Value & Analysis
Healthcare · TW · Market cap 11.4B TWD
Fair value as of: Jun 25, 2026
Analysis
Universal Vision Biotechnology Co (3218) currently trades at 133.50 TWD, while our model-based Fair Value estimate is 270.74 TWD — implying the stock looks roughly 102.8% undervalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. The company offers optical instruments, eyeglasses, contact lenses, and eyeglass accessories. It is also involved in eyeglasses optometry and dispensing services and leasing of medical devices. In addition, the company offers hospital management, optometric, and technical consultancy analysis, as well as provides medical and scientific prescription eyeglasses. Further, it offers sunglasses, fashionable and reading glasses, and progressive lenses for presbyopia. Additionally, the company provides contact lenses for myopia, hyperopia, presbyopia, and astigmatism; Universal lutein supplements; Universal eyemall; and ortho-k and other products for myopia control. Further, it offers wholesale and retail of medical equipment, western medicine; purchase and sale of ophthalmic surgical investments, medical optical tool; corporate and medical project investment, therapeutic, and consulting serv…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Universal Vision Biotechnology Co (3218) undervalued?
What is the fair value of 3218?
What is the quality score of 3218?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.